Literature DB >> 25734039

Incidence of breast cancer in fars province, southern iran: a hospital-based study.

Davood Mehrabani1, Amir Almasi2, Mahin Farahmand3, Z Ahrari1, Abbas Rezaianzadeh4, Golnoush Mehrabani1, Abdol Rasoul Talei5.   

Abstract

BACKGROUND: Breast cancer is still considered as one of the most common female cancers worldwide regardless of the countries' level of development. This study determines the incidence of breast cancer in Fars Province, Southern Iran.
METHODS: This study used patients' records from Shiraz University of Medical Sciences Cancer Registry Centre, which is a Hospital-Based Registry of Nemazee Hospital. Data were recorded based on International Classification of Diseases for Oncology (ICD-O) and compromised all invasive cancers in ICD-10 categories of C-00 to C-80. The findings were shown as the number of cases by site (ICD-10) and gender, with crude incidence (CRs), age-specific incidence and age-standardized incidence rates (ASRs) per 100,000 persons per year, performed by direct method using the world standard population.
RESULTS: The age group of 40-49 years had the highest rate of breast cancer and naturally most cases were post-menopause ones. Most cases were diagnosed in moderate differentiated state with an increasing trend. Early diagnosis of in situ neoplasms has not increased over time in comprised with malignant cases. The number of diagnosed cases has sharply increased after year 2004 especially during post-menopause period.
CONCLUSION: As the number of diagnosed cases has increased during post-menopausal period, screening and health programs seem necessary for menopause women.

Entities:  

Keywords:  Breast cancer; Incidence; Iran

Year:  2012        PMID: 25734039      PMCID: PMC4344961     

Source DB:  PubMed          Journal:  World J Plast Surg        ISSN: 2228-7914


INTRODUCTION

Breast cancer is still considered as one of the most common female cancers worldwide regardless of the countries’ level of development.[1] Its prevalence in Europe and USA was reported 8-10%, however, the lowest prevalence was noticed in Asian countries as 1%.[2] In Iran, the prevalence of breast cancer was reported as 6.7/1000 in 2002 and in ranking is the first among female malignancies[3],[4] comprising 24.4% of all neoplasms[5] with a crude incidence rate of 17.81[3] and an ASR of 23.65[3] in the year of 2006. In Fars Province, southern Iran, it is the first common cancer in females with a crude incidence of 11.58 and ASR of 18.06[6] with a 5 years survival rate of 58%.[7],[8] However, several studies specifically described the clinico-pathologic features, stages, and age distributions of breast cancer.[3]-[5],[9]-[17] It is difficult to predict the present and future patterns of breast cancer in Iran and carry out the most appropriate preventive and therapeutic measures to decrease the burden of the disease.[18] In addition, concerning the high mortality rate of breast cancer in developing countries[15] and its increasing incidence, an epidemiologic evaluation analysis focusing on the recent shift in the age of presentation should be considered for primary and secondary prevention of this cancer.[17],[19] Iran has a total population of just over 75 million and almost all studies of breast cancer in Iran are from the capital, Tehran with a population of approximately 14 million. Southern Iran has a population of approximately 4 million.[6] Geographical variations in incidence and mortality rates of breast cancer suggest that the known risk factors for breast cancer may vary in different parts of the world and that environmental factors are of greater importance than genetic factors.[20] For instance, in Iran; it has been shown that even after adjusting for age, young women are at relatively higher risk for developing breast cancer than are their Western counterparts.[9] Breast cancer begins in breast tissue, which is made up of glands for milk production, called lobules, and the ducts that connect lobules to the nipple. The remainder of the breast is made up of fatty, connective, and lymphatic tissue.[21] Breast cancer incidence and death rates generally increase with age. During 2002- 2006, 95% of new cases and 97% of breast cancer deaths occurred in women aged 40 and older.[21] Many of the known breast cancer risk factors, such as age, family history, age at first full-term pregnancy, early menarche, late menopause, and breast density, are not easily modifiable. However, other factors associated with increased breast cancer risk (postmenopausal obesity, use of combined estrogen and progestin menopausal hormones, alcohol consumption, and physical inactivity) are modifiable. Besides being female, age is the most important risk factor for breast cancer.[21] In this study we are trying to verify incidence rate of breast cancer in south Iran based on reports from Cancer Registry Center of Nemazee Hospital in Fars Province, Southern Iran and see if reported risk factors of breast cancer have changed. Women aging 15 years and older have been included in this study and several factors associated with breast cancer, like menopause status, pathology information and age, has been taken into consideration.

MATERIALS AND METHODS

This study used patients' records from Shiraz University of Medical Sciences Cancer Registry Centre, which is a Hospital-Based Registry of Nemazee Hospital, a tertiary care centre which delivers oncology services to a population of approximately four millions. In an active system, data were recorded in a sheet and coded based on ICD-O and all duplicate reports were eliminated. The personnel interviewed the patients to receive all information face-to-face. The registered cases comprised all invasive cancers in ICD-10 categories of C-00 to C-80. The cancer registry team actively collected and compiled the data for a period of 6 years from 2001 to 2006 from 4 hospitals of Shiraz University of Medical Sciences including Nemezee, Faghihi, Chamran and Zeynabieh hospitals comprising 87.8%, 8.3%, 1.7% and 2.2% of patient-referrals, respectively. As Nemezee Hospital is equipped with radio and chemotherapy centers, it supports most of the referrals. The findings were shown as the number of cases by site (ICD-10) and gender, with crude incidence (CRs), age-specific incidence and age-standardized incidence rates (ASRs) per 100,000 persons per year, performed by direct method using the world standard population. The data were statistically analyzed using SPSS (version 11.5, Chicago, IL, USA), and MS EXCEL (Microsoft, Raymond, WA, USA) softwares. A P value less than 0.05 was considered as significant. The primary site and morphology data were coded using the ICD-O.45 Information on other variables was coded as advised by International Agency For Research on Cancer (IARC). Women menopause age was considered 47 years based on previous studies in the target population.

RESULTS

Statistical data about age group of patients is being shown in Table 1. As is obvious from the table, the age group of 40-49 years had the highest rate of breast cancer and naturally most cases were post-menopause ones.
Table 1

Statistical data on age group of patients with breast cancer

Variables Total 2001 2002 2003 2004 2005 2006
AgeMean±SD 48.9±12.4 49.03±12.3 48.3±12.1 47±12.7 49.4±12 49.1±12 49.6±13
Median (min, max) 48 (15-95) 48 (22-95) 48 (22-84) 46 (18-90) 48 (20-84) 48 (19-94) 48 (15-90)
Age groups15-19 8 (0.4) 0 0 3 (1.1) 0 1 (0.2) 4 (0.8)
20-29 69 (3.5) 8 (3.5) 2 (2.5) 15 (5.7) 10 (3.5) 16 (3.4) 14 (2.8)
30-39 359 (18.1) 39 (17.1) 53 (22.3) 48 (18.3) 48 (16.7) 79 (16.6) 92 (18.6)
40-49 667 (33.6) 83 (36.4) 74 (31.1) 98 (37.3) 99 (34.4)169 (35.4)144 (29.1)
50-59 476 (23.9) 54 (23.7) 56 (23.5) 57 (21.7) 70 (24.3)125 (26.2)114 (23.1)
60-69 243 (12.2) 25 (11) 35 (14.7) 25 (9.5) 40 (13.9) 53 (11.1) 65 (13.2)
+ 70 166 (8.4) 19 (8.3) 14 (5.9) 17 (6.5) 21 (7.3) 34 (7.1) 61 (12.3)
Pre-menopause 962 (48.4)107 (46.9)115 (48.3)146 (55.5)138 (47.9)232 (48.6)224 (45.3)
Post-menopause1026 (51.6)121 (53.1)123 (51.7)117 (44.5)150 (52.1)245 (51.4)270 (54.7)
Number of breast cancer cases1988228238263288477494
Statistical data on age group of patients with breast cancer As is shown in Table 2, most cases from 2001 to 2006 were diagnosed in moderate differentiated state with an increasing trend. Unfortunately, early diagnosis (in situ neoplasm) has not increased over time in comparison with invasive malignant cases.
Table 2

Frequency distribution (%) of breast cancer in Fars Province, during 2001-2006.

Variables Total 2001 2002 2003 2004 2005 2006
Total1988228238263288477494
GradingWell differentiated 186 (9.4) 10 (4.4) 8 (3.4) 38 (14.4) 36 (12.5) 44 (9.2) 50 (10.1)
Moderate differentiated 593 (29.8) 24 (10.5) 37 (15.5) 92 (35)110 (38.2)154 (32.3)176 (35.6)
Poorly differentiated 228 (11.5) 9 (3.9) V4 (1.7) 42 (16) 32 (11.1) 80 (16.8) 61 (12.3)
Not determined or applicable 981 (49.3)185 (81.1)189 (79.4) 91 (34.6)110 (38.2)199 (41.7)207 (41.9)
BehaviorIn situ neoplasm 51 (2.6) 1 (0.4) 2 (0.8) 5 (1.9) 12 (4.2) 19 (4) 12 (2.4)
Malignant- primary site1937 (97.4)227 (9.6)236 (99.2)258 (98.1)276 (95.8)458 (96)482 (97.6)
TopographyNipple 12 (0.6) 1 (0.4) 1 (0.4) 1 (0.4) 4 (1.4) 1 (0.2) 4 (0.8)
Central portion 64 (3.2) 0 3 (1.3) 15 (5.7) 14 (4.9) 24 (5) 8 (1.6)
Upper inner qua. 43 (2.2) 2 (0.9) 3 (1.3) 6 (2.3) 4 (1.4) 9 (1.9) 19 (3.8)
Lower inner qua. 23 (1.2) 0 0 5 (1.9) 4 (1.4) 9 (1.9) 5 (1)
Upper outer qua. 258 (13) 6 (2.6) 11 (4.6) 51 (19.4) 49 (17) 79 (16.6) 62 (12.6)
Lower outer qua. 51 (2.6) 2 (0.9) 2 (0.8) 8 (3) 10 (3.5) 17 (3.6) 12 (2.4)
Axillary tail 2 (0.1) 0 0 0 0 0 2 (0.4)
Overlapping lesion 47 (2.4) 0 2 (0.8) 6 (2.3) 7 (2.4) 9 (1.9) 23 (4.7)
Breast , NOS1488 (74.8)217 (95.2)216 (90.8)171 (65)196 (68.1)329 (69)359 (72.7)
MorphologyNeoplasm, malignant 20 (1) 0 1 (0.4) 0 0 1 (0.2) 18 (3.6)
Carcinoma, NOS 45 (2.3) 15 (6.6) 6 (2.5) 5 (1.9) 5 (1.7) 11 (2.3) 3 (0.6)
Mucinous adenocaecinoma 14 (0.7) 2 (0.9) 4 (1.7) 3 (1.1) 0 3 (0.6) 2 (0.4)
Infiltrating duct carcinoma1622 (81.6)180 (78.9)188 (79)217 (82.5)244 (84.7)381 (79.9)412 (83.4)
Medullary carcinoma 118 (5.9) 11 (4.8) 21 (8.8) 15 (5.7) 21 (7.3) 29 (6.1) 21 (4.3)
Lobular carcinoma 94 (4.7) 17 (7.5) 9 (3.8) 11 (4.2) 12 (4.2) 28 (5.9) 17 (3.4)
Others 75 (3.8) 3 (1.3) 9 (3.8) 12 (4.6) 6 (2.1) 24 (5) 21 (4.3)

NOS: not otherwise specified

Frequency distribution (%) of breast cancer in Fars Province, during 2001-2006. NOS: not otherwise specified Figure 1 present the trend of breast cancer in Fars Province during these years demonstrating that the number of diagnosed cases has sharply increased in 2005.
Fig. 1

The trend of breast cancer incidence rate from 2001-2006 in Fars provinces.

The trend of breast cancer incidence rate from 2001-2006 in Fars provinces. Figure 2 clearly describes that number of diagnosed cases has sharply increased after 2004 during post-menopause period.
Fig. 2

The comparison incidence rate of breast cancer between pre and post menopause women.

The comparison incidence rate of breast cancer between pre and post menopause women.

DISCUSSION

Clinico-pathological reports of breast cancer in southern Iran describing the age and stage patterns of patients are so spare[6],[13] and we could not find any data comparing incidence of the disease in different time periods. In this report we tried to show the incidence of breast cancer in different age group of women and show how some reported risk factors were associated with this cancer, in southern Iran from 2002 to 2006. The incidence of this cancer has sharply increased especially after 2004, mainly after menopausal age. Some previous reports have shown that age of breast cancer is lower in Iran in comparison with western communities,[9] and our study confirmed this report. The median age of breast cancer incidence was reported 61 years in United States from 2002 to 2006[22] but in our study, this age was shown to be 48 years. Our population is a young one and the lower incidence age may be related to this factor. So age standardization was performed to avoid misinterpretations. The increase was shown in number of cases after menopause age that could be related to the increase in use of estrogen hormones after menopausal age. But these findings should be interpreted with caution as there is no report admitting increase of estrogen hormone use in southern Iran. Although there are some reports showing that use of these hormones can increase risk of breast cancer,[11],[12] some others reject this finding.[13],[14] However cause-specific mortality and the increment in incidence in most Asian countries are much higher than in Western countries,[15] which can be due to increased life expectancy and changes in reproductive and behavioral patterns associated with a heightened breast cancer risk.[16] As is shown in Table 3, we considered crude and age standardized rate (ASR) of breast cancer in Iran, as 18.9 and 25.06 respectively, but Musavi et al.[4] reported as 17.81 and 23.65.
Table 3

The breast cancer incidence rate in Fars cancer registry compared with other reports.

Different area Crude ASR of breast cancer
Fars Cancer Registry (2001-2006)20.76 19.12
Ardabil Cancer Registry[22] 4.71 7.6
Iran[5]18.9 25.06
Globocan (2000)[1]34.9 35.7
South Korea[23]32.2 26.2
European Union[24]-110.3
Switzerland[25]-110.5
Europe[26]- 94.3
The breast cancer incidence rate in Fars cancer registry compared with other reports. As the number of diagnosed cases in our study has increased during post-menopausal period, screening and health programs seem necessary for menopause women in our region.
  20 in total

Review 1.  ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics.

Authors:  K McPherson; C M Steel; J M Dixon
Journal:  BMJ       Date:  2000-09-09

2.  Screening for breast cancer in Iran: a challenge for health policy makers.

Authors:  Seyed Mohsen Mousavi; Iraj Harirchi; Mandana Ebrahimi; Mohammad Ali Mohagheghi; Ali Montazeri; Alireza Mousavi Jarrahi; Mohamamd Mehdi Gouya; Anthony B Miller
Journal:  Breast J       Date:  2008-10-13       Impact factor: 2.431

3.  Breast cancer in Iran: a review of 903 case records.

Authors:  I Harirchi; M Ebrahimi; N Zamani; S Jarvandi; A Montazeri
Journal:  Public Health       Date:  2000-03       Impact factor: 2.427

4.  Breast cancer survival in South Asian women in England and Wales.

Authors:  Sabya Farooq; Michel P Coleman
Journal:  J Epidemiol Community Health       Date:  2005-05       Impact factor: 3.710

5.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

6.  Cancer occurrence in Iran in 2002, an international perspective.

Authors:  Alireza Sadjadi; Mehdi Nouraie; Mohammad Ali Mohagheghi; Alireza Mousavi-Jarrahi; Reza Malekezadeh; Donald Maxwell Parkin
Journal:  Asian Pac J Cancer Prev       Date:  2005 Jul-Sep

7.  Use of oral contraceptives and risk of breast cancer in young women.

Authors:  G Ursin; R K Ross; J Sullivan-Halley; R Hanisch; B Henderson; L Bernstein
Journal:  Breast Cancer Res Treat       Date:  1998-07       Impact factor: 4.872

8.  Breast cancer in Iran: results of a multi-center study.

Authors:  Iraj Harirchi; Mojgan Karbakhsh; Amir Kashefi; Amir Javad Momtahen
Journal:  Asian Pac J Cancer Prev       Date:  2004 Jan-Mar

9.  Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

Authors:  Gerardo Heiss; Robert Wallace; Garnet L Anderson; Aaron Aragaki; Shirley A A Beresford; Robert Brzyski; Rowan T Chlebowski; Margery Gass; Andrea LaCroix; JoAnn E Manson; Ross L Prentice; Jacques Rossouw; Marcia L Stefanick
Journal:  JAMA       Date:  2008-03-05       Impact factor: 56.272

10.  Survival analysis of 1148 women diagnosed with breast cancer in Southern Iran.

Authors:  Abbas Rezaianzadeh; Janet Peacock; Daniel Reidpath; Abdolrasoul Talei; Seyed Vahid Hosseini; Davood Mehrabani
Journal:  BMC Cancer       Date:  2009-06-05       Impact factor: 4.430

View more
  9 in total

1.  Breast Cancer Incidence Trends in Isfahan Province Compared with those in England over the Period 2001-2013.

Authors:  Marziyeh H Ainvand; Najmeh Shakibaei; Zahra Ravankhah; Ghasem Yadegarfar
Journal:  Int J Prev Med       Date:  2021-05-27

2.  Tendency to breast reconstruction after breast mastectomy among Iranian women with breast cancer.

Authors:  Fatemeh Homaei Shandiz; Mona Najaf Najafi; Zahra Abbasi Shaye; Mahta Salehi; Maryam Salehi
Journal:  Med J Islam Repub Iran       Date:  2015-06-29

3.  Histopathological evaluation of reduction mammaplasty specimens to detect occult breast cancer: a report from southern iran.

Authors:  Mohammad Hossain Rajabian; Perikala Vijayananda Kumar
Journal:  World J Plast Surg       Date:  2012-07

4.  Breast implants and breast cancer.

Authors:  Davood Mehrabani; Ail Manafi
Journal:  World J Plast Surg       Date:  2012-07

5.  Self-Care Education Programs Based on a Trans-Theoretical Model in Women Referring to Health Centers: Breast Self-Examination Behavior in Iran

Authors:  Leila Ghahremani; Zakiyeh mousavi; Mohammad Hossein Kaveh; Haleh Ghaem
Journal:  Asian Pac J Cancer Prev       Date:  2016-12-01

6.  Patients With Breast Cancer: Report From a National Hospital-Based Cancer Registry in Argentina, 2012 to 2016.

Authors:  María Graciela Abriata; Guillermo Raúl Macías
Journal:  J Glob Oncol       Date:  2019-01

7.  New 5-D Coding System for Categorization of Plastic Surgery Conditions.

Authors:  Saurabh Gupta; Ravi Kumar Chittoria; Vinayak Chavan; Abhinav Aggarwal; Chirra Likhitha Reddy; Padmalakshami Bharathi Mohan; K Shijina; Imran Pathan
Journal:  World J Plast Surg       Date:  2019-09

Review 8.  Breast Reconstruction after Mastectomy in Women with Breast Cancer: A Systematic and Meta-Analysis Review.

Authors:  Amir Anbiyaiee; Mahrokh Abouali Galeh Dari; Omid Anbiyaee; Abolghasem Anbiyaiee
Journal:  World J Plast Surg       Date:  2020-01

9.  Polymorphisms in Phase I (CYP450) Genes CYP1A1 (rs4646421), CYP1B1 (rs1056836), CYP19A1 (rs749292) and CYP2C8 (rs1058930) and Their Relation to Risk of Breast Cancer: A Case-Control Study in Mazandaran Province in North of Iran.

Authors:  Golpar Golmohammadzadeh; Abbas Mohammadpour; Nematollah Ahangar; Mohammad Shokrzadeh
Journal:  Open Access Maced J Med Sci       Date:  2019-08-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.